Nexium Deceptive Marketing Action Tossed

Law360, New York (May 10, 2010, 3:20 PM EDT) -- A federal judge has dismissed a putative class action that alleged AstraZeneca Pharmaceuticals LP engaged in deceptive business practices by orchestrating a misleading marketing campaign for heartburn drug Nexium.

Judge Eduardo Robreno of the U.S. District Court for the District of Delaware on Thursday dismissed without prejudice a suit brought by the Pennsylvania Employee Benefit Trust Fund and others claiming Nexium was merely the drug Prilosec repackaged in a different form.

AstraZeneca obtained approval to sell Nexium the same year its patent on Prilosec expired, and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.